JMKX000623 vs VX-993

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Diabetic Peripheral Neuropathic Pain

Shared mechanism: Voltage-gated sodium channel NaV1.8 · full Diabetic Peripheral Neuropathic Pain pipeline

JMKX000623

Developed by Jemincare and partners

Phase 2 in Diabetic Peripheral Neuropathic Painsmall molecule
Partial signal

NCT06221241 · Phase 2 · status unknown

This randomized, quadruple-blind, placebo- and active-comparator-controlled phase 2 trial in 220 people with diabetic peripheral neuropathic pain is designed to compare change in average daily pain score against placebo over 12 weeks. Results have not yet been posted.

No aligned efficacy figure on record for this race.

VX-993

Developed by Vertex Pharmaceuticals

Phase 2 in Diabetic Peripheral Neuropathic Painsmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT06619860 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Diabetic Peripheral Neuropathic Pain

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJMKX000623VX-993
Average daily pain, change—Not reported—Not reported
30% pain reduction—Not reported—Not reported
50% pain reduction—Not reported—Not reported
Sleep interference, change—Not reported—Not reported

Average daily pain, change

JMKX000623
—Not reported
VX-993
—Not reported

30% pain reduction

JMKX000623
—Not reported
VX-993
—Not reported

50% pain reduction

JMKX000623
—Not reported
VX-993
—Not reported

Sleep interference, change

JMKX000623
—Not reported
VX-993
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

JMKX000623: no structured comparison results are available for Diabetic Peripheral Neuropathic Pain.

VX-993: no structured comparison results are available for Diabetic Peripheral Neuropathic Pain.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JMKX000623's landscape · VX-993's landscape